These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27371505)

  • 1. Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence.
    Mizoguchi H; Yamanaka T; Kano S
    Drug Discov Today; 2016 Oct; 21(10):1681-1689. PubMed ID: 27371505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis.
    Döring JH; Lampert A; Hoffmann GF; Ries M
    PLoS One; 2016; 11(8):e0161660. PubMed ID: 27557111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan diseases: state of the drug discovery art.
    Volmar CH; Wahlestedt C; Brothers SP
    Wien Med Wochenschr; 2017 Jun; 167(9-10):197-204. PubMed ID: 26819216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.
    Schlander M; Adarkwah CC; Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):171-9. PubMed ID: 25312018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE; van Weely S; Büller HA; Leufkens HG; de Vrueh RL
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regulatory overview about rare diseases.
    Llinares J
    Adv Exp Med Biol; 2010; 686():193-207. PubMed ID: 20824447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian Approaches for Confirmatory Trials in Rare Diseases: Opportunities and Challenges.
    Ursino M; Stallard N
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rare diseases. Concept, epidemiology and state of the question in Spain].
    Posada De la Paz M; Martín-Arribas C; Ramírez A; Villaverde A; Abitua I
    An Sist Sanit Navar; 2008; 31 Suppl 2():9-20. PubMed ID: 18953369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Orphan drugs: drugs for rare diseases].
    Schenk M
    Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
    [No Abstract]   [Full Text] [Related]  

  • 14. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rare diseases: an "exceptional field of research. Interview by Catherine Holué].
    Dolfus H; Lévy N
    Rev Prat; 2012 Jan; 62(1):89-90. PubMed ID: 22335076
    [No Abstract]   [Full Text] [Related]  

  • 16. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.